

iQnovate Ltd has commenced the process to be cross-listed on the NASDAQ Capital Markets

We are proud to announce that iQnovate Ltd (NSX:IQN, GXG: IQN, OTCQB: IQNDY) has commenced the process to list the company's depository receipts on the NASDAQ Capital Markets and upon admission will be trading under the ticker symbol "IQN".

The move to the NASDAQ Capital Markets will expose the company to a greater investor base, both retail and institutional. Upon admission, iQnovate would join an exchange with more than 3,500 listed companies with a market value of over \$9.1 trillion.

iQnovate Ltd Chief Executive Officer Dr George Syrmalis said, "the NASDAQ cross-listing was timely and strategic, and would greatly benefit the company's shareholders."

Dr Syrmalis further commented, "the Biotech Sector was one of the high performers of 2014. The sector greatly outperformed the broader market in that year. In 2014, the S&P 500 Biotechnology Index was up 43.6% and the NASDAQ Biotechnology Index was up 36.9%. In particular biotech, has more than doubled within the composite over the past 15 years. There is great investor interest in the biotech sector at the moment; there are some interesting very early stage biopharmaceutical compounds on the horizon", said Dr Syrmalis.

iQN is proud to share this milestone moment with our shareholders and friends. The iQN team takes this opportunity to thank you for your on-going support.

2015 will be an exciting and busy year executing a strategy which is constantly maturing.

Together with our shareholders we will share the journey of investing in the most innovative industry worldwide - the biotechnology industry.

Click [here](#) view the market announcement.

If you have any queries about the announcement, please contact our Investor Relations team investor.relations@iqnovate.com on +61 2 8239 5400.

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE

iQnovate Limited

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry. Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity. iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400 • Fax: +61 2 8362 9325

New York: 200 Park Avenue, Suite 1700, New York City, NY, USA 10166 •

London: 5 Harbour Exchange, Harbour Exchange Square, Canary Wharf E14 9GE UK •